相似文献
1
The best of times, the worst of times: the wealth and poverty of heart failure pharmacotherapies: is there a role for vesnarinone?
Drug Saf. 2004;27 Suppl 1:3 p following table of contents.
2
Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
Drug Saf. 2004;27 Suppl 1:11-8. doi: 10.2165/00002018-200427001-00003.
3
Clinical characteristics of vesnarinone.
Drug Saf. 2004;27 Suppl 1:1-9. doi: 10.2165/00002018-200427001-00002.
4
Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group.
N Engl J Med. 1993 Jul 15;329(3):149-55. doi: 10.1056/NEJM199307153290301.
5
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
N Engl J Med. 1998 Dec 17;339(25):1810-6. doi: 10.1056/NEJM199812173392503.
6
Review of a dose-dependent increase in mortality with vesnarinone among patients with severe heart failure.
Curr Cardiol Rep. 1999 May;1(1):31. doi: 10.1007/s11886-999-0038-4.
7
Vesnarinone for heart failure.
N Engl J Med. 1994 Jan 6;330(1):64; author reply 65. doi: 10.1056/NEJM199401063300114.
8
Quinolinone derivatives in the management of congestive heart failure.
Coron Artery Dis. 1994 Feb;5(2):107-11. doi: 10.1097/00019501-199402000-00003.
9
Vesnarinone for heart failure.
N Engl J Med. 1994 Jan 6;330(1):65.
10
The flosequinan experience and its implications.
Br J Hosp Med. 1993;50(11):683; author reply 683-4.
Zotero 插件